血脂康对不稳定型心绞痛患者OX-LDL、vWF和hs-CRP的作用研究  

Research of the function of Xuezhikang on OX-LDL,vWF and hs-CRP in patients with unstable angina

作　　者：唐召力[1] 滕秋叶[1] 覃碧云[1] 张治坤[1] 刘永明[1] 唐海莲[1] 陈海玉[1] 

机构地区：[1]南方医科大学附属柳州医院,广西柳州545007

出　　处：《现代中西医结合杂志》2011年第34期4323-4324,4446,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

基　　金：广西柳州市科技局科研课题(2008031405)

摘　　要：目的观察血脂康对不稳定型心绞痛(UA)患者氧化修饰低密度脂蛋白(OX-LDL)、血友病因子(vWF)和超敏C反应蛋白(hs-CRP)的作用。方法将215例UA患者随机分为2组:血脂康组104例,辛伐他汀组111例,治疗前及治疗3,6个月后,分别检测OX-LDL、vWF和hs-CRP,统计期间急性心肌梗死(AMI)的发生率。结果血脂康与辛伐他汀均能降低OX-LDL、vWF和hs-CRP水平,但血脂康降低vWF的幅度更大,且血脂康降低hs-CRP起效更快。二药对AMI发病率的影响无显著性差异。结论在保护血管内皮和控制血管炎症方面,血脂康比辛伐他汀更具优势。Objective It is to observe the effect of Xuezhikang on OX-LDL,vWF and hs-CRP in patients with unstable angina（UA）.Methods Two hundreds and fifteen patients with UA were randomly divided into two groups,of which 111 cases were in Simvastatin group and 104 cases were in Xuezhikang group.OX-LDL,vWF and hs-CRP level was measured before the treatment and at the third and sixth month after the treatment.The morbidity statistics of AMI in both groups was made at the end of the research.Results Both Xuezhikang and Simvastatin could reduce the level of OX-LDL,vWF and hs-CRP,but more powerful action on vWF and faster onset of action on hs-CRP of Xuezhikang was showed.There was no difference in the morbidity of AMI between the two groups.Conclusion The effect of protecting vessel endothelium and controlling vessel inflammation of Xuezhikang is better than that of Simvastatin.

关 键 词：血脂康 辛伐他汀 不稳定型心绞痛 OX-LDL VWF HS-CRP 

分 类 号：R541.4[医药卫生—心血管疾病]